DUBLIN, Sept. 5, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences.
Morgan Stanley 21st Annual Global Healthcare Conference
Date/Time: Monday, September 11, 2023 at 11:20 a.m. EDT (4:20 p.m. BST)
Cantor Fitzgerald Global Healthcare Conference
Date/Time: Wednesday, September 27, 2023 at 11:30 a.m. EDT (4:30 p.m. BST)
The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
About Alkermes plc
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Alkermes Contact:
Jamie Bernard
Investor Relations
+1 781 873 2402
| Last Trade: | US$29.83 |
| Daily Change: | -0.87 -2.83 |
| Daily Volume: | 1,116,912 |
| Market Cap: | US$4.920B |
October 28, 2025 October 22, 2025 September 08, 2025 July 29, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
